Risk of complications from bone metastases in breast cancer: implications for management

被引:125
|
作者
Plunkett, TA [1 ]
Smith, P [1 ]
Rubens, RD [1 ]
机构
[1] Guys Hosp, Acad Oncol Unit, London SE1 9RT, England
关键词
breast cancer; bone metastases; radiotherapy; bisphosphonates;
D O I
10.1016/S0959-8049(99)00331-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A retrospective analysis of 859 patients who developed bone metastases from breast cancer between 1975 and 1991 was performed in order to identify factors that predict for complications from skeletal disease. The patients were divided into four groups based on the sites of disease at diagnosis of skeletal metastases: bone disease only; bone and soft tissue disease: bone and pleuro-pulmonary disease. bone and liver disease. Patients with metastatic disease confined to the skeleton were most likely to develop a pathological fracture. The time to long bone fracture was similar for all groups, but the least number of such fractures occurred in patients with bone and liver metastases since their survival was shortest (median: 5.5 months; P<0.001). patients with bone metastases only were most likely to require radiotherapy to painful osseous deposits (P = 0.0001) and most rapidly developed spinal cord compression (P = 0.01. data not shown). The results suggest that patients with disease confined to the skeleton at the diagnosis of bone metastases are most likely to develop skeletal-related complications from advanced breast cancer. Such patients may benefit most from treatment with bisphosphonates. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:476 / 482
页数:7
相关论文
共 50 条
  • [1] Management of bone metastases in breast cancer
    Lipton A.
    Current Treatment Options in Oncology, 2005, 6 (2) : 161 - 171
  • [2] A STRATEGY FOR THE MANAGEMENT OF BONE METASTASES FROM BREAST-CANCER
    TUBIANAHULIN, M
    TURPIN, F
    GOUPIL, A
    FLOIRAS, JL
    DELOUCHE, G
    SEMAINE DES HOPITAUX, 1984, 60 (42): : 2955 - 2962
  • [3] MANAGEMENT OF BREAST-CANCER WITH BONE METASTASES
    CLAVEL, M
    BONE, 1991, 12 : S11 - S12
  • [4] ClodronateA Review of its Use in the Prevention of Bone Metastases and the Management of Skeletal Complications Associated with Bone Metastases in Patients with Breast Cancer
    Toni M. Dando
    Lynda R. Wiseman
    Drugs & Aging, 2004, 21 : 949 - 962
  • [5] Clodronate - A review of its use in the prevention of bone metastases and the management of skeletal complications associated with bone metastases in patients with breast cancer
    Dando, TM
    Wiseman, LR
    DRUGS & AGING, 2004, 21 (14) : 949 - 962
  • [7] Bisphosphonates in the management of breast cancer patients with bone metastases
    Arslan, Ulku Yalcintas
    Onder, Fatih Oguz
    Alkis, Necati
    TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, 2011, 26 (01): : 38 - 44
  • [8] A primer of bone metastases management in breast cancer patients
    Petrut, B.
    Trinkaus, M.
    Simmons, C.
    Clemons, M.
    CURRENT ONCOLOGY, 2008, 15 : S50 - S57
  • [9] Optimal management of bone metastases in breast cancer patients
    Wong, M. H.
    Pavlakis, N.
    BREAST CANCER-TARGETS AND THERAPY, 2011, 3 : 35 - 60
  • [10] Risk factors of bone metastases in early breast cancer
    Madej, B.
    Szumilo, J.
    Burdan, F.
    Radzikowska, E.
    Chroscicki, A.
    Maciejewski, R.
    BREAST, 2007, 16 : S25 - S25